260 related articles for article (PubMed ID: 7823579)
1. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
[TBL] [Abstract][Full Text] [Related]
2. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
3. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
4. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
6. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Bostwick DG; Burke HB; Wheeler TM; Chung LW; Bookstein R; Pretlow TG; Nagle RB; Montironi R; Lieber MM; Veltri RW
J Cell Biochem Suppl; 1994; 19():283-9. PubMed ID: 7529857
[TBL] [Abstract][Full Text] [Related]
7. Summary of recommendations for colonic biomarker studies of candidate chemopreventive compounds in phase II clinical trials.
Lipkin M
J Cell Biochem Suppl; 1994; 19():94-8. PubMed ID: 7823612
[TBL] [Abstract][Full Text] [Related]
8. Surrogate end-point biomarkers in chemopreventive drug development.
Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
[TBL] [Abstract][Full Text] [Related]
9. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic considerations in the evaluation of chemopreventive data.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet RA; Greenwald P; Hawk ET; Fay JR; Sigman CC
IARC Sci Publ; 1996; (139):203-19. PubMed ID: 8923032
[TBL] [Abstract][Full Text] [Related]
11. Target populations and strategies for chemoprevention trials of prostate cancer.
Bostwick DG
J Cell Biochem Suppl; 1994; 19():191-6. PubMed ID: 7823591
[TBL] [Abstract][Full Text] [Related]
12. Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.
Kelloff GJ; O'Shaughnessy JA; Gordon GB; Hawk ET; Sigman CC
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):593-6. PubMed ID: 12869396
[No Abstract] [Full Text] [Related]
13. Progress in clinical chemoprevention.
Kelloff GJ; Hawk ET; Karp JE; Crowell JA; Boone CW; Steele VE; Lubet RA; Sigman CC
Semin Oncol; 1997 Apr; 24(2):241-52. PubMed ID: 9129692
[TBL] [Abstract][Full Text] [Related]
14. Protocol design considerations that relate to demonstrating the safety and effectiveness of chemopreventive agents.
Johnson KA; Beitz J; Justice R; Schmidt W; Andrews P; DeLap R
J Cell Biochem Suppl; 1997; 27():1-6. PubMed ID: 9591186
[TBL] [Abstract][Full Text] [Related]
15. The role of chemoprevention in cancer control.
Greenwald P; Kelloff GJ
IARC Sci Publ; 1996; (139):13-22. PubMed ID: 8923016
[TBL] [Abstract][Full Text] [Related]
16. G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials.
Hemstreet GP; Rao J; Hurst RE; Bonner RB; Waliszewski P; Grossman HB; Liebert M; Bane BL
J Cell Biochem Suppl; 1996; 25():197-204. PubMed ID: 9027619
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention trials in the cervix: design, feasibility, and recruitment.
Mitchell MF; Hittelman WN; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Hong WK
J Cell Biochem Suppl; 1995; 23():104-12. PubMed ID: 8747384
[TBL] [Abstract][Full Text] [Related]
18. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
19. [Chemoprevention of cancer. Prevention of cancer in groups with increased risk].
Sanner T; Dybing E
Tidsskr Nor Laegeforen; 1996 Aug; 116(19):2329-33. PubMed ID: 8804210
[TBL] [Abstract][Full Text] [Related]
20. Smokers and urinary genotoxins: implications for selection of cohorts and modulation of endpoints in chemoprevention trials.
De Flora S; Camoirano A; Bagnasco M; Bennicelli C; van Zandwijk N; Wigbout G; Qian GS; Zhu YR; Kensler TW
J Cell Biochem Suppl; 1996; 25():92-8. PubMed ID: 9027604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]